⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

Official Title: A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer

Study ID: NCT02857270

Study Description

Brief Summary: The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.

Detailed Description:

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Georgetown University Medical Center, Washington, District of Columbia, United States

Florida Cancer Specialists, Sarasota, Florida, United States

Massachusetts General Hospital, Boston, Massachusetts, United States

Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

Sarah Cannon Cancer Center, Nashville, Tennessee, United States

Tennessee Oncology PLLC, Nashville, Tennessee, United States

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

St Vincent's Hospital, Sydney, New South Wales, Australia

Linear Clinical Research Ltd, Nedlands, Western Australia, Australia

Gustave Roussy, Villejuif Cedex, , France

Shizuoka Cancer Center, Sunto-Gun, Shizuoka, Japan

National Cancer Center Hospital, Chuo-ku, Tokyo, Japan

Contact Details

Name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Affiliation: Eli Lilly and Company

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: